Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

VACCELERAID

Financiado

Cerrado

A novel vaccine technology leading to accelerated availability of vaccines and i...

A novel vaccine technology leading to accelerated availability of vaccines and improved delivery Common to current manufacturing technologies for vaccines is the long lead-time before they were made available or novel vaccines could be made available to the public. Current methods are very time consuming and frequently encoun... ver más

30/04/2017

Geza Ad ltd

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

GEZA AD LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-04-30

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

Geza Ad ltd

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BIO2014-54588-P MAQUINARIAS REPLICATIVAS DE VIRUS RNA: DE LA ESTRUCTURA Y ME... 278K€ Cerrado

ARCAS ARCAS Analysis of the Route to Commercialisation of MVA bas... 164K€ Cerrado

OSIRIX Revolutionary vaccines to prevent pandemic and seasonal outb... 4M€ Cerrado

BFU2017-90018-R LA GRIPE EN EL MICROSCPIO: VISUALIZANDO SUS PROCESOS MOLECUL... 160K€ Cerrado

SupraRNA A Comprehensive Supramolecular Approach for an RNA vaccine f... 213K€ Cerrado

DESARROLLO DE VACUNAS TERMOESTABLES BASADAS E... DESARROLLO DE VACUNAS TERMOESTABLES BASADAS EN MRNA FRENTE A... 2M€ Cerrado

Duración del proyecto: 4 meses Fecha Inicio: 2016-12-07
Fecha Fin: 2017-04-30

Líder del proyecto

GEZA AD LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Common to current manufacturing technologies for vaccines is the long lead-time before they were made available or novel vaccines could be made available to the public. Current methods are very time consuming and frequently encounter problems with scale-up, in particular if sudden demands have to be met. However, the ability to start vaccination campaigns fast – and earlier than currently possible – is particularly important in view of seasonal influenza, influenza pandemics or sudden outbreaks of dangerous, hereto unknown infectious diseases. Resulting delays definitely pose a high risk for health and lives of many people. To provide solutions to these world-wide challenges is of European and global interest and GZA offers such a response: The technology is based on self-assembly of SV40 capsid proteins around a given nucleic acid and has several additional applications; however, it will be validated here in the area of vaccination with RNA. The main advantage of GZA’s novel vaccine technology platform is that it enables strongly shortened manufacturing periods and accelerated market introduction of a novel vaccine (e.g., 2-3 times faster manufacturing for novel influenza vaccines). The business model is based on developing and validating the technology for a given purpose in-house and receive milestone payments and royalties specified in co-development and licensing agreements with established pharma companies active in the vaccine sector (such as GSK, Novartis or Sanofi Pasteur). Most importantly, in the feasibility assessment applied for here GZA wishes to further detail the business plan with updated evaluations of markets, competitors, IP, a project/development plan and budget to further highlight the attractiveness of the business case and to prepare initiation of a full development program in phase 2. Furthermore, it is intended to obtain input from experienced regulatory professionals and draft a potential regulatory strategy aiming at marketing approval.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores